Subscribe
OleksSH / Shutterstock.com
17 September 2024NewsAmericasLiz Hockley

Sandoz wins $137.2m payout for lost profits in generic launch

Court finds United Therapeutics breached settlement agreement by restricting distribution of cartridges | Sandoz alleged rival hampered launch of generic medication for pulmonary arterial hypertension

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

More features

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
Gilead deal staves off generic HIV drugs for another six years
Apple voids Omni MedSci wearable tech patent
Clifford Chance expands life sciences team with A&O Shearman hire
Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ
'A very good decision’: Patent industry welcomes UPC in-house reps update
Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan